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Abstract
Background & Aims: Hepatocellular carcinoma (HCC) is the second most
common cause of cancer deaths worldwide. The global HCC BRIDGE study
was a multiregional, large-scale, longitudinal cohort study undertaken to
improve understanding of real-life management of patients with HCC, from
diagnosis to death. Methods: Data were collected retrospectively from Janu-
ary 2005 to September 2012 by chart reviews of eligible patients newly diag-
nosed with HCC at participating institutions. Results: Forty-two sites in 14
countries contributed final data for 18 031 patients. Asia accounted for 67%
of patients, Europe for 20% and North America for 13%. As expected, the
most common risk factor was hepatitis C virus in North America, Europe
and Japan, and hepatitis B virus in China, South Korea and Taiwan. The
most common Barcelona Clinic Liver Cancer stage at diagnosis was C in
North America, Europe, China and South Korea, and A in Taiwan and Japan.
Across all stages, first HCC treatment was most frequently transarterial
chemoembolization in North America, Europe, China and South Korea, per-
cutaneous ethanol injection or radiofrequency ablation in Japan and resec-
tion in Taiwan. Survival from first HCC treatment varied significantly by
region, with median overall survival not reached for Taiwan and 60, 33, 31,
24 and 23 months for Japan, North America, South Korea, Europe and
China respectively (P < 0.0001). Conclusions: Initial results from the
BRIDGE study confirm previously reported regional trends in patient demo-
graphic characteristics and HCC risk factors, document the heterogeneity of
treatment approaches across regions/countries and underscore the need for
earlier HCC diagnosis worldwide.
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Worldwide, liver cancer is the fifth most common can-
cer in men and ninth most common in women (1), with
hepatocellular carcinoma (HCC) accounting for >90%
of primary liver cancer cases (2). In 2012, there were
approximately 782 000 new cases and 746 000 deaths
from liver cancer worldwide, making it the second most
common cause of cancer deaths (after lung cancer) (1).
The greatest burden of HCC is in the developing world,
with cases in eastern and southeastern Asia, and central
and western Africa accounting for more than 80% of
the total; 50% of all cases occur in China alone (1).
In most cases, HCC develops in cirrhotic livers, and
cirrhosis is the strongest risk factor for the disease (3).
The variation in incidence and prevalence of HCC by
geographical region is primarily a result of regional dif-
ferences in exposure to causal factors for cirrhosis, such
as hepatitis B virus (HBV) in Asia and sub-Saharan
Africa and hepatitis C virus (HCV) in the West and
Japan (2–4). Dietary ingestion of fungal aflatoxins has
also been recognized as a major risk factor in southern
Asia and sub-Saharan Africa (5). Although the incidence
of HCC has historically been low in North America and
Europe, there is evidence for a significant upward trend
in the United States in recent years (6, 7), which has
been attributed to an increased prevalence of HCV
infection (8). The rise in obesity and diabetes world-
wide, particularly in North America and Europe, is also
leading to recognition of non-alcoholic fatty liver dis-
ease as a significant contributor to the aetiology of HCC
(8).
Potentially curative treatments for HCC include sur-
gery (resection or transplant), radiofrequency ablation
(RFA) and percutaneous ethanol injection (PEI);
approximately 30–40% of HCC patients globally who
are diagnosed with very early (Stage 0) or early (Stage
A) disease are eligible for these procedures (2, 9–11).
For patients with intermediate stage disease (Stage B),
transarterial chemoembolization (TACE) is recom-
mended to establish local control and palliation (3).
Approximately 25–70% of patients with HCC are
diagnosed with advanced-stage disease, which is
regarded as incurable (6, 7, 12–14). Patients with
advanced HCC have limited treatment options, and
chemotherapy provides minimal clinical benefit (14).
Sorafenib, a multitargeted kinase inhibitor, is the only
systemic agent shown to extend overall survival (OS)
compared with placebo in patients with advanced HCC
(15). However, the survival benefit with sorafenib is
modest (a 2- to 3-month extension in median OS com-
pared with placebo in two phase III trials) (16, 17), and
there is a pressing need for more effective therapies for
patients with advanced HCC.
The outcome for patients with HCC treated in ran-
domized clinical trials is unlikely to fully reflect out-
comes in daily clinical practice, as the patient
populations in each setting are likely to differ consider-
ably (18). Clinical trials employ strict eligibility criteria
and, in the case of HCC, are often limited to patients
with good liver function to avoid confounding results.
Because patients treated in clinical practice may have
less thorough follow-up and patient counselling, com-
pliance may be reduced compared with that in clinical
trials. Real-world observational studies are needed to
gain better insight into the management of patients with
HCC (19).
The global HCC BRIDGE (‘Bridge to Better Out-
comes in HCC’) study was the first multiregional, large-
scale, longitudinal cohort study to document the HCC
patient experience from diagnosis to death, and aimed
to include all patients, regardless of treatment received
(20). The objective was to provide an improved under-
standing of global patterns of HCC therapy and associ-
ated outcomes across real-world clinical practice, with
data collected retrospectively from patient charts.
Patients were recruited from Asia, Europe and North
America, and data were captured for both systemic and
non-systemic treatments with the intent to assess HCC
management in the real-world setting and compare it
with that recommended by therapeutic guidelines, for
example the Barcelona Clinic Liver Cancer (BCLC)
guidelines recommended by the American Association
for the Study of Liver Diseases (AASLD) (9) and the
European Association for the Study of the Liver (EASL)
(2).
Here, we describe the methodology of the BRIDGE
study and present an overview of the final data from the
full cohort of study patients.
Patients and methods
Study design, patients and data collection
The BRIDGE study was a real-world, observational,
longitudinal cohort study, with data collected from 1
Key Points
• The global HCC BRIDGE (‘Bridge to Better Out-
comes in HCC’) study was the first multiregional,
large-scale, longitudinal cohort study to document
the HCC patient experience from diagnosis to death.
• The objective was to provide an improved under-
standing of global patterns of HCC therapy and asso-
ciated outcomes across real-world clinical practice.
• The study showed the pattern of initial and second
recorded treatments in real practice.
• These results confirm previously reported regional
trends in patient demographic characteristics and
HCC risk factors, document treatment heterogeneity
across regions/countries, and underscore the need for
earlier HCC diagnosis worldwide.
Liver International (2015)
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd2156
Global patterns of liver cancer management Park et al.
January 2005 to 30 September 2012. The primary
objective was to assess current treatment approaches
and associated clinical outcomes in HCC. Secondary
objectives were to assess and compare the characteris-
tics of patients with HCC treated with sorafenib or
with other therapies in the same time period, and to
evaluate the treatment pattern and resource use. The
study was done in accordance with ethical principles
based on those in the current Declaration of Helsinki,
and was consistent with International Conference on
Harmonization Good Clinical Practice guidelines,
Good Epidemiology Practices and applicable regulatory
requirements.
Eligible patients were male or female; aged 18 years
or older; newly diagnosed with HCC between 1 January
2005 and 30 June 2011 in accordance with AASLD,
EASL or comparable local guidelines (2, 9, 21, 22); and
who received or were receiving HCC treatment through
a selected study site. Patients whose primary treatment
was via participation in a randomized clinical trial were
excluded; similarly, patients who, at a later point in time
consented to take part in a clinical trial, were with-
drawn, with the exception of patients entering single-
arm trials or adjuvant treatment trials. Other exclusion
criteria were unknown date of HCC diagnosis or
unknown date of first visit for HCC at a given study site.
Sites were instructed to enrol all eligible patients on a
sequential basis, with data to be extracted on a rolling
basis from patient charts by personnel at the study site.
A selection scheme was employed to cap enrolment at
specific sites when the number of eligible patients
exceeded the number allowed by power calculation. Sea-
sonality was avoided by distributing the number of
patients entered in a given cohort year based on month
of diagnosis (e.g. if 120 patients were entered as part of
a cohort, the first 10 eligible patients diagnosed each
month would be entered). Study data were entered into
a web-based, electronic data-capture system developed
by Outcome Sciences, Inc. (Cambridge, MA, USA), and
subject to rigorous monthly monitoring and cleaning.
Key data collected included patient demographics; HCC
risk factors; selected laboratory values required to stage
patients; tumour characteristics; HCC-directed therapy;
and outcomes. Data on resource use in addition to
treatment (e.g. physician visits, type and date of assess-
ments) were also collected.
Study sites
Criteria for site selection included tertiary referral centre
providing surgical and routine follow-up care of HCC;
oncology centres treating patients with HCC; patient
population with HCC aetiologies consistent with the
national average (by type and proportion); and centres
utilizing HCC screening practices in accordance with
national standards. Centres with a patient population
previously used to represent the national population for
other research purposes (i.e. development of staging
systems, or determination of national incidence or
prevalence rates) were also considered. Study sites are
listed in Table S1.
Data analysis
The results reported here were based on the final data
set, including all available data as of September 30,
2012. All eligible patients enrolled in the study were
included in the analysis population, with information
from patients who did not complete follow-up included
in the analyses, unless the patient requested otherwise.
The primary measure of treatment outcome was OS, as
measured from date of first HCC treatment to death (to
be consistent with clinical trial data). Secondary mea-
sures of treatment outcome included evidence of disease
progression (yes/no), systemic treatment-limiting
adverse event and systemic treatment failure, as well as
the time to each of these events (also measured from
date of starting treatment). Patient follow-up was
defined as date of HCC diagnosis or first date on record
at the site where the patient was seen for HCC, which-
ever was earlier, until death or end of study, whichever
came first. An ongoing effort to limit the amount of
missing data was made by alerting sites to missing data
identified during monthly monitoring and cleaning. No
missing value imputation technique was applied in the
present analysis.
Results are presented as descriptive statistics, based
on patients for whom data were available; results for
which data are missing for >30% of patients are noted.
OS was estimated using Kaplan-Meier methods, with
analyses by BCLC stage and by region reported here.
Data are available to perform analyses on OS by treat-
ment type; however, initial results suggested the need
for further study, which was considered to be beyond
the scope of this initial report. Cox proportional hazards
models were used to test for significance and all
reported P-values are two-sided.
Results
Patient demographics and clinical status at diagnosis
As of September 30, 2012, a total of 42 sites in 14 coun-
tries had participated in the study (Fig. 1). Data were
available for a total of 18 031 patients treated for HCC
[Asia: 15 sites, n = 12 031 (67% of patients); Europe: 23
sites, n = 3673 (20%) and North America: four sites,
n = 2326 (13%)]. Because of the large percentage of
patients from China, and also because of substantial dif-
ferences in risk factors and treatment patterns between
all four Asian countries included, results for the Asian
countries are presented separately (either by all four
countries separately or by China, separately from
grouped Taiwan, South Korea and Japan). The study
Liver International (2015)
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included a total of 8683 patients from China (72% of
Asian patients and 48% of all patients); 1587 patients
from Taiwan (13% of Asian patients); 1227 patients
from South Korea (10% of Asian patients); and 534
patients from Japan (4% of Asian patients).
The most common risk factor for HCC was HCV in
North America, Europe and Japan, and HBV in China,
South Korea and Taiwan (Table 1). Alcoholic liver dis-
ease was a substantially higher risk factor in North
America and Europe than in any Asian country. In
North America, Europe and South Korea, at least 40%
of patients reported past or current alcohol abuse, and
more than 50% of patients reported past or current
tobacco use; these rates were lower in China, Taiwan
and Japan. Median alpha-fetoprotein (AFP) varied
greatly between the regions. Patients from North Amer-
ica, Europe, Taiwan and Japan had median AFP in the
range of 17–25 ng/ml, while median AFP was 101 ng/
ml for South Korean patients and 219 ng/ml for Chi-
nese patients.
Among patients with known staging information, the
most common BCLC stage at diagnosis was stage C in
North America, Europe, China and South Korea, and
stage A in Taiwan and Japan (see Table 1). In Taiwan
and Japan, approximately 70% of patients were diag-
nosed with HCC at BCLC stage 0 or A, and less than
20% were diagnosed at BCLC stage C or D. In all other
regions or countries (North America, Europe, China
and South Korea), more than 50% of HCC cases were
stage C or D at diagnosis. Using the Child-Pugh scoring
system, the most common status at diagnosis was A
across all regions and countries, although the propor-
tion of A was much higher in China, Taiwan and Japan
(~90%) compared with North America and Europe
(~70%). Median tumour diameter at diagnosis ranged
from 2.5–6.7 cm, with the largest median tumour diam-
eter observed in Chinese patients. The highest inci-
dences of portal vein invasion or thrombosis and
extrahepatic spread occurred in South Korea (29 and
10%, respectively), followed by China and North Amer-
ica. Across regions/countries, most patients had Eastern
Cooperative Oncology Group/World Health Organiza-
tion (ECOG/WHO) performance status grade (23) of 0
or 1 (≥87% per region) and Karnofsky scores (24) of
80–100 (≥79% per region).
First and second recorded treatments
First recorded HCC treatment varied substantially
between regions (Fig. 2A). Across all disease stages,
TACE was most frequently used first in North America,
Europe, China and South Korea, while PEI or RFA were
most frequently used first in Japan; in Taiwan, resection
was the most common first treatment (see Fig. 2A). For
patients with BCLC stage 0–C at diagnosis, resection,
TACE and PEI or RFA were the most frequently used
first treatments, while palliative care was most fre-
quently used in patients with stage D disease (Fig. 2B).
The most common second treatment following first
treatment with resection, TACE or PEI/RFA varied by
Total number of sites = 42
North America = 4
Europe = 23
Asia-Pacific = 15
United States
2 sites
Canada
2 sites
Italy
2 sites
Germany
2 sites
France
6 sites
Spain
3 sites
China
12 sites
South Korea
1 site
Taiwan
1 site
United 
Kingdom
5 sites Sweden
2 sites
Austria
2 sites
Portugal
1 site
Japan
1 site
Fig. 1. Distribution of sites participating in the HCC BRIDGE study by country.
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Table 1. Patient demographics and clinical characteristics at diagnosis (N = 18 031)
Variable/group*
North America
n = 2326
Europe
n = 3673
China
n = 8683
Taiwan
n = 1587
South Korea
n = 1227
Japan
n = 534
Age, mean (SD) 62 (11) 65 (11) 52 (12) 61 (12) 57 (10) 69 (9)
Gender (male), n (%) 1786 (77) 2860 (78) 7497 (86) 1143 (72) 1021 (83) 340 (64)
Comorbidities, n (%)
Tobacco use† 1187 (61) 1759 (54) 3042 (36) 531 (34) 802 (69) 173 (39)
Alcohol abuse† 759 (40) 1459 (44) 2034 (24) 287 (18) 779 (67) 7 (2)
HCC risk factors, n (%)‡ n = 2243 n = 3466 n = 8538 n = 1580 n = 1172 n = 446
HBV 522 (23) 362 (10) 6575 (77) 987 (63) 884 (75) 64 (14)
HCV 876 (39) 1590 (46) 255 (3) 489 (31) 112 (10) 284 (64)
ALD 471 (21) 1290 (37) 416 (5) 66 (4) 110 (9) 59 (13)
NASH 275 (12) 334 (10) 53 (1) 84 (5) 68 (6) 9 (2)
AFP, ng/mL n = 2023 n = 2922 n = 8048 n = 1572 n = 1169 n = 445
Median 24 17 219 25 101 18
Child-Pugh status, n (%) n = 2051 n = 2513 n = 7859 n = 1559 n = 1164 n = 442
A 1458 (71) 1801 (72) 6819 (87) 1439 (92) 911 (78) 390 (88)
B 469 (23) 627 (25) 960 (12) 115 (7) 228 (20) 49 (11)
C 124 (6) 85 (3) 80 (1) 5 (<1) 25 (2) 3 (1)
BCLC stage, n (%) n = 1588§ n = 2261§ n = 6501 n = 1461 n = 1152 n = 433
0 107 (7) 84 (4) 192 (3) 213 (15) 82 (7) 107 (25)
A 474 (30) 582 (26) 1973 (30) 810 (55) 290 (25) 206 (48)
B 157 (10) 253 (11) 591 (9) 176 (12) 149 (13) 62 (14)
C 673 (42) 1158 (51) 3606 (55) 250 (17) 605 (53) 53 (12)
D 177 (11) 184 (8) 139 (2) 12 (1) 26 (2) 5 (1)
Tumour diameter, cm¶ n = 2081 n = 3163 n = 6984 n = 1467 n = 1160 n = 433
Median 3.8 3.5 6.7 3.5 4.4 2.5
Range 0.8–28 0.1–35 0.5–28 0.5–22 0.2–25 0.7–18
Multiple tumours n = 2198 n = 3324 n = 7131 n = 1535 n = 1160 n = 433
Yes/no (%) 39/61 44/56 29/71 26/74 49/51 34/66
Any portal vein invasion or thrombosis n = 2199 n = 3290 n = 7828 n = 1561 n = 1162 n = 439
Yes/no (%) 19/81 14/86 23/77 10/90 29/71 10/90
Any extrahepatic spread n = 2200 n = 3302 n = 7888 n = 1558 n = 1162 n = 439
Yes/no/not assessed (%) 8/90/2 4/85/11 8/62/31 2/97/1 10/90/<1 3/95/3
ECOG/WHO performance
status grade, n (%)**
n = 1736 n = 3051 n = 8363 n = 1565 n = 1169 n = 443
0 907 (52) 1328 (44) 3445 (41) 1286 (82) 734 (63) 403 (91)
1 621 (36) 1325 (43) 4663 (56) 238 (15) 414 (35) 33 (7)
>1 208 (12) 398 (13) 255 (3) 41 (3) 21 (2) 7 (2)
Karnofsky score, n (%)†† n = 1430 n = 1670 n = 8327 n = 1563 n = 1169 n = 2
<50 59 (4) 12 (1) 59 (1) 5 (<1) 0 (0) 0 (0)
50–70 238 (17) 200 (12) 352 (4) 40 (3) 239 (20) 0 (0)
80–100 1133 (79) 1458 (87) 7916 (95) 1518 (97) 930 (80) 2 (100)
AFP, alpha-fetoprotein; ALD, alcoholic liver disease; BCLC, Barcelona Clinic Liver Cancer; ECOG/WHO, Eastern Cooperative Oncology Group/World Health
Organization; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; SD, standard deviation.
*Statistics based on patients with known values.
†Past or current.
‡Percentages were calculated among patients evaluated for HCC risk factors; patients who were not evaluated had missing data and were not
included in the calculations.
§Data missing in >30% of patients.
¶Includes patients with missing number of measurable lesions who had values for ‘largest diameter in liver.’
**A greater ECOG/WHO performance status grade indicates worse health status (5 = death; 0 = asymptomatic).
††A greater Karnofsky score indicates better health status (100 = normal, no complaints, and no evidence of disease; 0 = death).
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region, but was most often another non-systemic ther-
apy (Fig. 3). After resection, TACE was the most fre-
quently recorded second treatment for HCC in all
analysis groups apart from Europe, where PEI/RFA were
used more frequently. TACE was also the most common
second treatment for HCC after PEI/RFA in all regions
apart from North America, where liver transplant was
more common. Second treatments showed greatest vari-
ation by region after first-line TACE; transplant was
most frequently used in North America, PEI/RFA in
grouped Taiwan, South Korea and Japan, sorafenib in
Europe, and palliative care in China.
Survival analyses
OS from first HCC treatment by BCLC stage is shown
in Fig. 4A. Median OS was not reached for BCLC stage
0, and was 80, 27, 15 and 4 months for BCLC stages A,
B, C and D respectively (P < 0.0001). Median OS was
34 months among patients who could not be staged by
the BCLC staging system. There was significant varia-
tion in survival from first HCC treatment by region
(Fig. 4B). Median OS was not reached for Taiwan and
60, 33, 31, 24 and 23 months for patients from Japan,
North America, South Korea, Europe and China respec-
tively (P < 0.0001).
Discussion
This report describes the first global and largest-to-
date observational study in patients with HCC, pro-
viding a valuable opportunity to learn from real-
world practice in managing this disease. The study
data also allow some assessment of the merit of treat-
Pa
tie
nt
s,
 %
*
North America Europe China Taiwan JapanSouth Korea
60
40
20
0
Transplant
PEI/RFA
Other systemic therapy†
Resection TACE
Other locoregional therapy‡ Sorafenib
Radiotherapy Palliative care
Pa
tie
nt
s,
 %
§
Stage DStage BStage AStage 0 Stage C
80
60
40
20
0
Transplant
PEI/RFA
Other systemic therapy†
Resection TACE
Other locoregional therapy‡ Sorafenib
Radiotherapy Palliative care
(A)
(B)
Fig. 2. First recorded HCC treatment by country/region (A) and BCLC stage (B). *Percentages are based on percent of population with
known values. †Any systemic therapy other than sorafenib, e.g., doxorubicin, gemcitabine, cisplatin, or other cytotoxic or biological agent.
‡Any locoregional therapy not clearly PEI/RFA or TACE, e.g., transarterial radioembolization (TARE) or cryoablation. §Percentages are based
on number of patients with data available; total may add up to >100% if more than one treatment was started concurrently. PEI, percutane-
ous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.
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ment guidelines based on the results of rigorously
conducted clinical trials.
Demographic characteristics and HCC risk factors at
diagnosis in the BRIDGE study appeared to confirm
well-known trends. The high prevalence of male
patients in this study support previous findings that
HCC is up to four times more commonly diagnosed
in males than in females (1, 25, 26)]. Similarly, the
predominant risk factors identified in the BRIDGE
study are consistent with those previously reported
(25, 27), comprising HBV infection in Asian countries
(excluding Japan) and HCV infection in Europe,
North America and Japan. The younger mean age at
diagnosis in China (and, to some extent, also in South
Korea) may reflect vertical transmission of HBV from
mother to infant (4). Although HBV was also the most
common risk factor in Taiwan, the proportion of
affected patients (63%) was lower than in China and
South Korea (77 and 75%, respectively), and the mean
age at diagnosis in Taiwan was older and similar to
that in North America. These observations suggest that
the universal HBV vaccination program in Taiwan,
which has led to a significant decline in HBsAg carrier
rates in the Taiwanese population, may also be
influencing the epidemiology of HCC in this country
(28, 29).
The BCLC staging system, which incorporates patient
performance status, number and size of nodules, cancer
symptoms and liver function, has been proposed as a
standard method to determine prognosis and guide
treatment selection among patients with HCC by the
AASLD and EASL clinical practice guidelines (2, 9). In
the BRIDGE study, the predominant BCLC stage at
diagnosis was stage C in all regions or countries apart
from Japan and Taiwan. The high rate of advanced-stage
disease at diagnosis underscores the need for earlier
diagnosis of HCC, and suggests that surveillance efforts
for HCC could be improved in many countries.
Although Japan, Taiwan and South Korea have all intro-
duced surveillance programs (30–33), government-
funded or national surveillance programs have yet to be
established in China (32, 33), or in countries in Europe
or North America.
The observed differences in disease stage at diagnosis
(later in South Korea compared with Taiwan and Japan)
and median OS (31 months for South Korea compared
with not reached in Taiwan and 60 months in Japan)
suggest that surveillance programs in Japan and Taiwan
may have been more effective than the program in
South Korea, although data from the single site in South
Korea may not well reflect the general outcome for the
country-wide program. These results could also reflect
differences in surveillance program design (with respect
to screening tools used, frequency of testing and target
population), in implementation and uptake (affected by
the proportion of population funded by the government
and commitment of clinicians) or a mixture of these
factors. Whether patients were diagnosed during sur-
veillance was a data point captured for each patient in
this study. However, the way this question was under-
stood by personnel entering data appears to have dif-
fered across the participating sites, precluding our
ability to clearly assess the influence of surveillance on
the overall study results. Evidence from one of the par-
ticipating sites in the United States does suggest that
surveillance can have a positive effect on patient out-
comes. In a retrospective analysis of all patients diag-
nosed with HCC from 2007–2009 (n = 460) at the
Mayo Clinic in Rochester, Minnesota, patients diag-
nosed during surveillance had less advanced disease,
First recorded
therapy
Region
North America (18%)
Europe (16%)
Asia-T/SK/J  (33%)
China (32%)
North America (33%)
Europe (29%)
Asia-T/SK/J  (35%)
China (51%)
North America (18%)
Europe (28%)
Asia-T/SK/J  (16%)
China (4%)
Most common second
recorded treatment †
Resection
TACE
TACE (31%)
TACE (43%)
TACE (72%)
TACE (54%)
TACE (48%)
TACE (59%)
Transplant (32%)
Transplant (34%)
Palliative (31%)
Sorafenib (26%)
PEI/RFA (33%)
PEI/RFA (36%)
PEI/RFA
Fig. 3. Second recorded HCC treatment after first recorded resection, TACE, or PEI/RFA. *Combination therapy was not defined in the
BRIDGE data; however, patients treated with either PEI or RFA were pooled together. †Percentages are based on percentage of population
with known values. ‡Includes grouped patients from Taiwan (n = 1587; 47%), South Korea (n = 1227; 37%), and Japan (n = 534; 16%).
PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.
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were more likely to be eligible for potentially curative
treatments and had increased survival times (after
40 months of follow up, median OS not reached in
patients diagnosed during surveillance vs. 12.5 months
in patients not diagnosed during surveillance,
P < 0.001) (34).
While widely recognized to be essential for the effec-
tive treatment of patients with the disease, surveillance-
supported early diagnosis of HCC also results in
lead-time bias that increases OS (35). This is consistent
with our finding of superior OS (not adjusted for lead-
time bias) for patients in Taiwan and Japan when com-
pared with China, Europe, South Korea and North
America (see Fig. 4B). However, there were also differ-
ences in survival between regions or countries where the
distribution of stage at diagnosis was similar; for exam-
ple, median OS in North America and South Korea was
better than that observed in Europe or China. This may
reflect variation in data collection, patient populations
(other than stage at diagnosis) or variation in manage-
ment including treatment patterns. As expected, median
OS decreased with progressing BCLC stage (see
Fig. 4A), supporting the prognostic utility of the BCLC
staging system. Our estimates of 27, 15 and 4 months
for median OS for BCLC stages B, C and D, respectively,
are somewhat higher than those reported for clinical tri-
als in the literature: ~20 months for BCLC stage B (36),
~10 months for BCLC stage C treated with sorafenib in
the SHARP trial (16) and 3 months for BCLC stage D
(36).
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Fig. 4. Survival estimates from first HCC treatment by BCLC stage (A) and country/region (B), with number of subjects at risk and 95% Hall-
Wellner bands (shaded colours). *Results shown are unadjusted and impacted to unknown degrees by lead-time and selection bias, as well
as by censoring that decreases reliability with increasing time.
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The BRIDGE study showed differences in choice of
first treatment by region and stage at diagnosis. In early-
stage disease (stage 0 or stage A), for which resection,
liver transplant or RFA/PEI are recommended by the
AASLD/EASL guidelines as potentially curative treat-
ments (2, 9), PEI/RFA, resection and TACE were the
most frequently used first treatments. The use of TACE
in these patients is inconsistent with the AASLD/EASL
guidelines. However, some of these cases may be
explained by the use of TACE as neoadjuvant therapy,
highlighting a possible limitation in the way the data
were collected. Indeed, pre-operative TACE has been
used extensively in patients with resectable HCC,
although a systematic review of the literature has con-
cluded that TACE in this setting does not improve dis-
ease-free survival (37). TACE is also frequently used
prior to liver transplantation, and approximately 30%
of patients receiving TACE in North America subse-
quently underwent liver transplantation (see Fig. 3). An
additional explanation for TACE in BCLC stage A is that
these patients are either unfit or partial responders to
curative therapies. In North America, a fair number of
patients who were candidates for transplantation instead
received TACE or RFA as first treatment, which may
have also resulted in down-staging. Although combina-
tion therapy with TACE or RFA plus transplantation
was the actual intention, TACE/RFA and transplanta-
tion were counted separately given the observational
nature of the BRIDGE study.
Despite the known efficacy of liver transplantation,
only a minority of patients received this procedure.
Possible reasons include ineffective or non-existent
identification and surveillance of transplant-suitable
candidates, as well as limited availability of organ
donors. However, data on whether patients were placed
on a transplant registry were not collected as part of the
BRIDGE study, limiting its ability to further inform on
this issue. It should also be recognized that the treat-
ment patterns observed were also likely influenced by
substantial regional differences in practice related to
access and cost. While all participating centres likely
reflect the best care that can be delivered in each coun-
try, what constitutes best care in a resource-rich country
(e.g. the United States) will differ from best care offered
in less resource-rich countries (e.g. China). Given this
difference, it is perhaps not surprising that transplant
and systemic therapy with sorafenib, two resource-
intensive treatments, were used more frequently in
North America and Europe than elsewhere. In addition,
in countries with nationalized healthcare and limited
resources, the use of transplant and high-cost/low-bene-
fit treatments like sorafenib are likely to be constrained
by public policies aimed at delivering benefits broadly
across the population in need.
The BCLC treatment algorithm, adopted by AASLD/
EASL guidelines, recommends the use of sorafenib for
stage C disease (2). However, in the real-world BRIDGE
study, use of sorafenib as first recorded treatment was
low, despite the high number of patients diagnosed with
BCLC stage C disease. Since sorafenib efficacy is consid-
ered modest, many physicians may have tried to reduce
the tumour burden directly by locoregional therapies,
which could be expected to result in survival gain. Alter-
natively, the use of first-line sorafenib may have been
affected by intercountry variations in access, as noted
above. Rather than sorafenib, TACE and resection were
the most frequent first recorded treatments for patients
with stage C disease. This finding underscores the
unmet need for evaluating the outcome of surgical
resection vs. locoregional therapy vs. systemic therapy
in advanced stage HCC (14, 38). In patients with BCLC
stage D disease, the proportion who received palliative
care was surprisingly low across these real-world set-
tings, and the proportion who received liver transplant
was surprisingly high. This may have reflected liver
transplantation of patients with Child-Pugh class C or
ECOG/WHO performance status greater than 2 who
otherwise have liver disease meeting Milan criteria. It is
unclear, however, what proportion of stage D patients
received best supportive care [as recommended by the
BCLC treatment algorithm and by the Asian Pacific
Association for the Study of the Liver (APASL) consen-
sus guidelines (2, 35)], which may not always have been
captured in our data collection under ‘palliative care’. In
our analysis, any patient who did not receive a definitive
therapy was assumed to have received best supportive
care only.
Analysis of first recorded treatment by region shows
that sorafenib was used more frequently in North Amer-
ica, Europe and South Korea, compared with China,
Taiwan and Japan, possibly reflecting later regulatory
approval as well as reduced access to sorafenib in Asia.
Additionally, resection and TACE were the most fre-
quently recorded first treatments in China, Taiwan and
South Korea, compared with TACE and PEI/RFA in
Europe and Japan, and TACE, PEI/RFA and resection in
North America. This variation in first recorded treat-
ment by region may be because of real differences in the
accepted management strategies in Western countries,
where the BCLC treatment algorithm is most widely
used, compared with Asian countries, where other
guidelines predominate. The latter include Japanese
guidelines for HCC first compiled in 2005 (21, 39),
South Korean guidelines initially published in 2003 and
updated in 2009 (22), and the APASL consensus guide-
line for treatment of HCC (35). Further analysis of how
such regional guidelines might have influenced the prac-
tice patterns reported here, particularly in China, is
ongoing.
The primary strengths of the BRIDGE study are the
large patient population, wide geographical spread and
the capture of real-world clinical practice data from
patient charts. However, as with all observational cohort
studies, the BRIDGE study also has many limitations.
Because it is a medical chart-review study, the robust-
ness of the data depends on the thoroughness of each
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site’s understanding and documentation of medical his-
tory, treatment and response. Missing data and loss of
patients to follow-up are additional limitations of obser-
vational studies and may affect the results and their
interpretation. Although substantial effort was made to
encourage complete collection of all requested data at
the participating sites, there are some results reported
here (as noted in Table 1) for which the proportion of
missing data was >30%. In addition, it is possible that
the results are not generalizable because the study was
performed at tertiary referral centres, which might be
expected to provide the best care available in each coun-
try. In an attempt to maximize generalization of results
across a particular country, study sites were selected
where patient populations had HCC etiologist consis-
tent with previously reported national patterns. In the
case of single sites within one country (Taiwan, South
Korea and Japan), sites were additionally chosen to be
representative of the practice of other centres in the
country. However, it is possible that more treatable
patients with better liver function and good perfor-
mance status may have been enrolled, thereby introduc-
ing a selection bias. In particular, the lack of enrolled
BCLC stage D patients in China (2%), as well as the low
proportion with Child-Pugh stage B and C (12 and 1%,
respectively), suggest that such patients were not seen at
the participating sites and may therefore not have been
included in the study. Similarly, the relatively low rates
of patients reporting alcohol abuse in China, Taiwan
and Japan suggest that such patients also may not have
been treated at the participating sites for some reason
(for example, such patients might be expected to be less
likely to seek and receive care at a tertiary centre, and
less likely to be supported in doing so). These low rates
could also, however, reflect under-reporting because of
the possible stigma associated with admitting such abuse
in some countries. WHO estimates of per capita alcohol
consumption (litres of pure alcohol) for 2011 were 9.4
for the United States, 12.2 for Europe, 5.9 for China,
14.8 for South Korea and 8.0 for Japan (40). Given these
figures and the known strong interaction between alco-
hol abuse and other risk factors for HCC, the reported
rates of alcohol abuse for China (24%), Taiwan (18%)
and especially Japan (2%) seem unexpectedly low. These
conjectures regarding potentially ‘missing’ advanced-
stage patients may help to explain the possibly higher-
than-expected median OS reported here for China. They
could also contribute to the superior OS seen here for
Taiwan and Japan, but this more likely can be attributed
to the aforementioned lead-time bias, as well as, particu-
larly in the case of Taiwan, artificial inflation because of
the effects of censoring, which makes the OS reported
here increasingly less reliable with time. Finally, interac-
tions between variables in such a large sample size as the
population in this study are hard to control, and our
results must accordingly be interpreted with caution.
In conclusion, these real-world findings from the
BRIDGE study provide a broad overview of the current
state of HCC treatment and document the heterogeneity
of treatment approaches across regions and in different
countries. Results from the study confirm previously
reported regional trends in patient demographic charac-
teristics and HCC risk factors, underscore the need for
earlier diagnosis of HCC worldwide, and also suggest
that treatment guidelines may benefit from re-evalua-
tion. The data from Taiwan and Japan, in particular,
suggest it may be possible to improve outcomes by
focusing on identifying high-risk individuals and then
following them with surveillance to achieve early detec-
tion. It is hoped that information obtained from the
BRIDGE study will help identify unmet clinical needs
and contribute to the development of new treatment
paradigms that ultimately improve outcomes in patients
with HCC. The study has generated a very large dataset
which could potentially be used to address unanswered
research hypotheses and is available for further analysis
by interested investigators. Additional analyses of poten-
tial value could include the aforementioned survival by
treatment type, including systemic vs. non-systemic
therapy, assessment of regional practice vs. regional
guidelines, as well as exploratory identification of possi-
ble predictors of survival, such as changes in tumour
size or AFP levels over time.
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